Why Lineage Cell Therapeutics, Inc.’s (LCTX) Stock Is Up 5.32%
As of Tuesday, November 17, Lineage Cell Therapeutics, Inc.’s LCTX share price has surged by 5.32%, which has investors questioning if this is right time to sell.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Michael Rose
Michael Rose
Michael Rose
| Share Statistics | LCTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $213.9 | $213.9 | 30% |
|
| Shares Out (Mil) | 259.1 | 55.4 | 80% |
|
| Institutional Ownership | 84.5% | 93.3% | 52% |
|
| Float (Mil) | 193.2 | 40.6 | 73% |
|
| Beta | 1.69 | 0.98 | 87% |
|
| Avg Daily Volume (000s) | 3,148 | 597 | 86% |
|
| Price Change (52-week) |
(51.8%) | 40.9% | 19% |
|
| Growth | LCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.0% | 13.2% | 96% |
|
| Net Income (5yr) | (25.3%) | (10.7%) | 17% |
|
| EPS (5yr) | (14.9%) | 15.5% | 19 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.4%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.035) | ($0.090) | ($0.110) | |
| Month Ago EPS | $0.008 | ($0.065) | ($0.138) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.008 | ($0.062) | ($0.102) | |
| Year/Year Chg | 16.7% | (67.4%) | (137.3%) | |
| Financials | LCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $39 | 9% |
|
| Net Income (TTM) (Mil) | $2 | ($44) | 40% |
|
| EPS (TTM) | $0.007 | ($1.400) | 39% |
|
| Operating Cash Flow (TTM) (Mil) | ($26) | ($34) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($14) | $-0 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | $189 | $135 | 27% |
|
| Valuation | LCTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.11 | 1.97 | 70% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | LCTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (95.0%) | 67.9% | 2% |
|
| Net Margin | 16.2% | (50.8%) | 74% |
|
| ROA | 1.8% | (47.5%) | 53% |
|
| ROE | 3.9% | (51.9%) | 40% |
|
| Liabilities to Assets | 34.1% | 29.7% | 25% |
|
| F-Score | 4 | 3 | 33% |
|
Lineage Cell Therapeutics, Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors